Saponins from Saponaria officinalis L. Augment the Efficacy of a Rituximab-Immunotoxin

Planta Medica

Volumn 82, Issue 18, 2016, Pages 1525-1531

  Gilabert Oriol, Roger ^a,c   Thakur, Mayank ^a   Haussmann, Katy ^a   Niesler, Nicole ^a   Bhargava, Cheenu ^a   Görick, Cornelia ^b   Fuchs, Hendrik ^a   Weng, Alexander ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

anti CD22; anti CD25; Caryophyllaceae; immunotoxin; Rituximab; Saponaria officinalis; saponin; Saporin

Indexed keywords

IMMUNOTOXIN; RITUXIMAB; SAPORIN; RIBOSOME INACTIVATING PROTEIN 1; SAPONIN;

ARTICLE; B CELL LYMPHOMA CELL; CELL GROWTH; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG PURITY; DRUG SPECIFICITY; ELECTROPHORESIS; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKEMIA; SAPONARIA; SAPONARIA OFFICINALIS; B CELL LYMPHOMA; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; ISOLATION AND PURIFICATION; PATHOLOGY;

CELL LINE; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SYNERGISM; HUMANS; IMMUNOTOXINS; LYMPHOMA, B-CELL; RIBOSOME INACTIVATING PROTEINS, TYPE 1; RITUXIMAB; SAPONARIA; SAPONINS;

EID: 84978121083     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0042-110495     Document Type: Article

References (31)

1. Vincken J P Heng L de Groot A Gruppen H Saponins, classification and occurrence in the plant kingdom Phytochemistry 2007 68 275 297
2. Francis G Kerem Z Makkar H P Becker K The biological action of saponins in animal systems: a review Bri J Nutr 2002 88 587 605
3. Böttger S Melzig M F Triterpenoid saponins of the Caryophyllaceae and Illecebraceae family Phytochem Lett 2011 4 59 68
4. Gilabert-Oriol R Mergel K Thakur M von Mallinckrodt B Melzig M F Fuchs H Weng A Real-time analysis of membrane permeabilizing effects of oleanane saponins Bioorg Med Chem 2013 21 2387 2395
5. Weng A Thakur M von Mallinckrodt B Beceren-Braun F Gilabert-Oriol R Wiesner B Eichhorst J Bottger S Melzig M F Fuchs H Saponins modulate the intracellular trafficking of protein toxins J Control Release 2012 164 74 86
6. Moniuszko-Szajwaj B Masullo M Kowalczyk M Pecio Ł Szumacher-Strabel M Cieślak A Piacente S Oleszek W Stochmal A Highly polar triterpenoid saponins from the roots of Saponaria officinalis L Helv Chim Acta 2016 99 347 354
7. Polito L Bortolotti M Mercatelli D Battelli M G Bolognesi A Saporin-S6: a useful tool in cancer therapy Toxins 2013 5 1698 1722
8. Thakur M Weng A Pieper A Mergel K von Mallinckrodt B Gilabert-Oriol R Gorick C Wiesner B Eichhorst J Melzig M F Fuchs H Macromolecular interactions of triterpenoids and targeted toxins: role of saponins charge Int J Biol Macromol 2013 61 285 294
9. Gilabert-Oriol R Thakur M von Mallinckrodt B Bhargava C Wiesner B Eichhorst J Melzig M F Fuchs H Weng A Reporter assay for endo/lysosomal escape of toxin-based therapeutics Toxins 2014 6 1644 1666
10. Gilabert-Oriol R Thakur M von Mallinckrodt B Hug T Wiesner B Eichhorst J Melzig M F Fuchs H Weng A Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells Mol Pharm 2013 10 4347 4357
11. Gilabert-Oriol R Weng A Mallinckrodt B Melzig M F Fuchs H Thakur M Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy Curr Pharm Des 2014 20 6584 6643
12. Thakur M Mergel K Weng A Frech S Gilabert-Oriol R Bachran D Melzig M F Fuchs H Real time monitoring of the cell viability during treatment with tumor-targeted toxins and saponins using impedance measurement Biosens Bioelectron 2012 35 503 506
13. Baer Ii W H Maini A Jacobs I Barriers to the access and use of rituximab in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia: a physician survey Pharmaceuticals (Basel) 2014 7 530 544
14. Ghetie M A Bright H Vitetta E S Homodimers but not monomers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin Blood 2001 97 1392 1398
15. Guclu-Ustundag O Mazza G Saponins: properties, applications and processing Crit Rev Food Sci Nutr 2007 47 231 258
16. Weng A Thakur M Beceren-Braun F Bachran D Bachran C Riese S B Jenett-Siems K Gilabert-Oriol R Melzig M F Fuchs H The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins Mol Oncol 2012 6 323 332
17. Wayne A S Fitzgerald D J Kreitman R J Pastan I Immunotoxins for leukemia Blood 2014 123 2470 2477
18. Pescovitz M D Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action Am J Transplant 2006 6 859 866
19. Dotan E Aggarwal C Smith M R Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin's lymphoma P T 2010 35 148 157
20. Amoroso A Hafsi S Militello L Russo A E Soua Z Mazzarino M C Stivala F Libra M Understanding rituximab function and resistance: implications for tailored therapy Front Biosci (Landmark Ed) 2011 16 770 782
21. Riaz W Hernandez-Ilizaliturri F J Czuczman M S Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms Immunol Res 2010 46 192 205
22. Polito L Bolognesi A Tazzari P L Farini V Lubelli C Zinzani P L Ricci F Stirpe F The conjugate rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine Leukemia 2004 18 1215 1222
23. Holmes S E Bachran C Fuchs H Weng A Melzig M F Flavell S U Flavell D J Triterpenoid saponin augmention of saporin-based immunotoxin cytotoxicity for human leukaemia and lymphoma cells is partially immunospecific and target molecule dependent Immunopharmacol Immunotoxicol 2015 37 42 55
24. Drexler H G Guide to Leukemia-Lymphoma Cells Lines 2nd Edition. Braunschweig, Germany DSMZ 2010
25. Walshe C A Beers S A French R R Chan C H Johnson P W Packham G K Glennie M J Cragg M S Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling J Biol Chem 2008 283 16971 16984
26. James S E Greenberg P D Jensen M C Lin Y Wang J Till B G Raubitschek A A Forman S J Press O W Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane J Immunol 2008 180 7028 7038
27. Tembhare P R Marti G Wiestner A Degheidy H Farooqui M Kreitman R J Jasper G A Yuan C M Liewehr D Venzon D Stetler-Stevenson M Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia Am J Clin Pathol 2013 140 813 818
28. Du X Beers R Fitzgerald D J Pastan I Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity Cancer Res 2008 68 6300 6305
29. Weng A Jenett-Siems K Schmieder P Bachran D Bachran C Gorick C Thakur M Fuchs H Melzig M F A convenient method for saponin isolation in tumour therapy J Chromatogr B Analyt Technol I Biomed Life Sci 2010 878 713 718
30. Heisler I Keller J Tauber R Sutherland M Fuchs H A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins Int J Cancer 2003 103 277 282
31. Gilabert-Oriol R Thakur M Weise C Dernedde J von Mallinckrodt B Fuchs H Weng A Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression Protein Expr Purif 2013 91 54 60